[go: up one dir, main page]

PE20070163A1 - Composicion inmunogenica de conjugados de sacaridos de n. meningitidis - Google Patents

Composicion inmunogenica de conjugados de sacaridos de n. meningitidis

Info

Publication number
PE20070163A1
PE20070163A1 PE2006000719A PE2006000719A PE20070163A1 PE 20070163 A1 PE20070163 A1 PE 20070163A1 PE 2006000719 A PE2006000719 A PE 2006000719A PE 2006000719 A PE2006000719 A PE 2006000719A PE 20070163 A1 PE20070163 A1 PE 20070163A1
Authority
PE
Peru
Prior art keywords
meningitidis
immunogenic composition
priests
conjugates
protein
Prior art date
Application number
PE2006000719A
Other languages
English (en)
Inventor
Ralph Leon Biemans
Dominique Boutriau
Philippe Denoel
Jan Poolman
Pierre Duvivier
Carine Capiau
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070163(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20070163A1 publication Critical patent/PE20070163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)

Abstract

REFERIDA A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE POLISACARIDOS CAPSULARES DE N. MENINGITIDIS DE UNO DE LOS SEROGRUPOS A, C, W135 E Y CONJUGADOS CON UNA PROTEINA VEHICULO PARA PRODUCIR UN CONJUGADO DE POLISCARIDO CAPSULAR DE N. MENINGITIDIS, EN LA QUE EL TAMANO MEDIO DE CADA POLISACARIDO ES SUPERIOR DE 50 KDa. LA PROTEINA VEHICULO SE SELECCIONA DE TOXOIDE TETANICO (TT), TOXOIDE DIFTERICO (DT), CRM197, FRAGMENTO C DE TT Y PROTEINA D. LOS POLISACARIDOS CAPSULARES DE N SE CONJUGAN CON LA PROTEINA VEHICULO MEDIANTE UN ENGARCE BIFUNCIONAL, DE PREFERENCIA DICHO ENGARCE ES HIDRAZIDA DEL ACIDO ADIPICO (ADH). TAMBIEN ESTA REFERIDA A UNA VACUNA QUE COMPRENDE A DICHA COMPOSICION INMUNOGENICA
PE2006000719A 2005-06-27 2006-06-23 Composicion inmunogenica de conjugados de sacaridos de n. meningitidis PE20070163A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Publications (1)

Publication Number Publication Date
PE20070163A1 true PE20070163A1 (es) 2007-03-01

Family

ID=36716943

Family Applications (6)

Application Number Title Priority Date Filing Date
PE2006000718A PE20070123A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2010000450A PE20110072A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2014001334A PE20142165A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2006000719A PE20070163A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
PE2010000444A PE20110096A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica que comprende sacaridos de neisseria meningitidis conjugados a toxoide tetanico
PE2006000720A PE20070499A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PE2006000718A PE20070123A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2010000450A PE20110072A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2014001334A PE20142165A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2010000444A PE20110096A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica que comprende sacaridos de neisseria meningitidis conjugados a toxoide tetanico
PE2006000720A PE20070499A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica

Country Status (36)

Country Link
US (13) US8398983B2 (es)
EP (11) EP3009146B1 (es)
JP (9) JP5280199B2 (es)
KR (7) KR101351870B1 (es)
CN (3) CN103083657B (es)
AP (1) AP2436A (es)
AR (3) AR056396A1 (es)
AT (3) ATE536884T1 (es)
AU (7) AU2006263944B2 (es)
BE (1) BE2012C042I2 (es)
BR (5) BRPI0612670B8 (es)
CA (5) CA2612963C (es)
CY (5) CY1109996T1 (es)
DE (1) DE602006013313D1 (es)
DK (7) DK1896061T3 (es)
EA (4) EA012506B1 (es)
ES (9) ES2741529T3 (es)
FR (1) FR22C1008I2 (es)
HR (4) HRP20110567T4 (es)
HU (7) HUE047211T2 (es)
IL (8) IL187924A (es)
LT (2) LT2351578T (es)
LU (2) LU92085I2 (es)
MA (4) MA29602B1 (es)
MX (5) MX2007016236A (es)
MY (3) MY147490A (es)
NL (1) NL300549I2 (es)
NO (4) NO345422B1 (es)
NZ (6) NZ564605A (es)
PE (6) PE20070123A1 (es)
PL (8) PL1896062T3 (es)
PT (8) PT2283857T (es)
SI (8) SI2283857T1 (es)
TW (5) TWI537001B (es)
UA (2) UA95237C2 (es)
WO (6) WO2007000342A2 (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227613B1 (en) * 2000-06-29 2011-09-28 Glaxosmithkline Biolog Sa Vaccine composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN102319427A (zh) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
MX348734B (es) 2005-09-01 2017-06-27 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vacunacion multiple que incluye meningococcus del serogrupo c.
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
EP1973564B1 (en) 2005-12-22 2016-11-09 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
SI2004225T1 (sl) 2006-03-22 2012-08-31 Novartis Ag Reĺ˝imi za imunizacijo z meningokoknimi konjugati
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
WO2009000826A1 (en) * 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5701058B2 (ja) 2007-10-19 2015-04-15 ノバルティス アーゲー 髄膜炎菌ワクチン処方物
WO2010023216A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
EP2349520B1 (en) 2008-10-27 2016-05-25 GlaxoSmithKline Biologicals SA Purification method for carbohydrate from group a streptococcus
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
EP2424562B1 (en) * 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
PE20110065A1 (es) * 2009-06-22 2011-01-31 Wyeth Llc Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
EP3199177A1 (en) * 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
HUE034544T2 (hu) 2010-08-23 2018-02-28 Wyeth Llc Neisseria meningitidis rLP2086 antigént tartalmazó stabil készítmények
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
WO2013114268A1 (en) * 2012-01-30 2013-08-08 Serum Institute Of India Ltd. Immunogenic composition
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101784644B1 (ko) 2012-03-09 2017-10-11 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
SG10201706671WA (en) 2012-11-30 2017-09-28 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
WO2014147044A1 (en) * 2013-03-18 2014-09-25 Glaxosmithkline Biologicals S.A. Method of treatment
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
IN2014DE02450A (es) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
NZ760783A (en) * 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3131576B1 (en) 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
TWI684460B (zh) * 2015-07-21 2020-02-11 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
MY199399A (en) * 2016-03-15 2023-10-25 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Novel polysaccharide-protein conjugates and process to obtain thereof
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
PT3506935T (pt) * 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
HRP20191966T4 (hr) 2016-09-13 2022-09-16 Allergan, Inc. Stabilizirani neproteinski klostridijalni pripravci toksina
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3577130A2 (en) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis compositions and methods thereof
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
WO2019145981A1 (en) * 2018-01-29 2019-08-01 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
MX2023005517A (es) 2020-11-13 2023-08-21 Glaxosmithkline Biologicals Sa Novedosos portadores y métodos de conjugación.
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021710A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
DE3040825A1 (de) 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5180815A (en) 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
US5115924A (en) 1988-05-31 1992-05-26 Beatrice Konig-Haug Shelf system
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RU2105568C1 (ru) 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
EP2289548A3 (en) 1992-05-23 2012-08-08 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising hepatitis B surface antigen and other antigens
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2126616T3 (es) 1992-10-27 1999-04-01 American Cyanamid Co Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
EP0636252B1 (en) 1992-12-14 1998-03-18 I/O EXPLORATION PRODUCTS (U.S.A.), Inc. Hydraulic seismic actuator
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
WO1996029094A1 (en) 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
CZ390297A3 (cs) 1995-06-07 1998-05-13 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína
BRPI9609414B8 (pt) 1995-06-23 2021-05-25 Smithkline Beecham Biologicals S A combinação de vacina e kit para produzir a mesma.
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69709690T2 (de) 1996-10-23 2002-09-12 Matsushita Electric Industrial Co., Ltd. Optische Platte
ES2277362T5 (es) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO1999013906A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
CZ2001622A3 (cs) 1998-08-19 2002-01-16 North American Vaccine, Inc. Imunogenní konjugát polysacharid-protein s ß-propionamidovým spojením výhodný jako vakcina produkovaná za pouľití N-akryloylovaného polysacharidu
AU1626199A (en) † 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
EP2050464B1 (en) 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
AU2875700A (en) 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
WO2001000790A1 (en) 1999-06-25 2001-01-04 American Cyanamid Company Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
PT1233784E (pt) 1999-12-02 2008-11-03 Novartis Vaccines & Diagnostic Composições e métodos para a estabilização de moléculas biológicas após a liofilização
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
HU227613B1 (en) * 2000-06-29 2011-09-28 Glaxosmithkline Biolog Sa Vaccine composition
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2284182A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
DK2332581T3 (en) * 2001-01-23 2015-10-05 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
WO2003078453A1 (en) * 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
WO2003080678A1 (en) * 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP1506007B1 (en) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
EP1524990A2 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
BRPI0315228A8 (pt) 2002-10-11 2018-04-03 Chiron Srl Vacinas de polipeptídeo para ampla proteção contra linhagens meningocócicas hipervirulentas
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
PT1556477T (pt) * 2002-11-01 2017-11-14 Glaxosmithkline Biologicals Sa Processo de secagem
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
CN102319427A (zh) * 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
BRPI0408094A (pt) 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN104225587B (zh) 2003-05-07 2017-07-21 赛诺菲巴斯德公司 多价脑膜炎球菌衍生的多糖‑蛋白质缀合物及疫苗
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US9173931B2 (en) * 2003-08-06 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing polysaccharide-protein conjugate vaccines
JP2007502980A (ja) * 2003-08-21 2007-02-15 アプレラ コーポレイション Ｍａｌｄｉ質量分析法のためのマトリックス干渉の軽減
DE602004028262D1 (de) * 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
PL1961426T3 (pl) * 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
PT1742659E (pt) 2004-04-05 2013-06-03 Pah Usa 15 Llc Emulsões de óleo em água microfluidizadas e composições de vacinas
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
DK1740217T3 (da) * 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2580137A1 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20060121055A1 (en) 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2425855A1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2533248T3 (es) * 2005-05-06 2015-04-08 Novartis Ag Inmunógenos para vacunas contra Meningitidis A
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
MX348734B (es) 2005-09-01 2017-06-27 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vacunacion multiple que incluye meningococcus del serogrupo c.
EP2336777B1 (en) * 2005-09-05 2013-04-03 GlaxoSmithKline Biologicals s.a. Serum bactericidal assay for N. meningitidis specific antisera
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1973564B1 (en) 2005-12-22 2016-11-09 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2633789A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
KR20150038626A (ko) * 2006-03-17 2015-04-08 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
AU2007233705B2 (en) * 2006-03-30 2010-12-23 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2008001224A2 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
CA2658393A1 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
NZ575273A (en) * 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
US8885224B2 (en) 2007-03-14 2014-11-11 Konica Minolta Business Technologies, Inc. Information embedding method, its program and information embedding device
WO2008135514A1 (en) * 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2010023216A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
MX373250B (es) * 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN103124737A (zh) * 2010-03-11 2013-05-29 葛兰素史密丝克莱恩生物有限公司 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗
CN102781322B (zh) * 2010-06-11 2015-02-25 松下电器产业株式会社 语音听取的评价系统、及方法
AU2012335208B2 (en) * 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
WO2013114268A1 (en) * 2012-01-30 2013-08-08 Serum Institute Of India Ltd. Immunogenic composition
US10124051B2 (en) * 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
SG11201503861UA (en) * 2012-12-05 2015-06-29 Glaxosmithkline Biolog Sa Immunogenic composition
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015299008B2 (en) * 2014-08-05 2018-08-02 Glaxosmithkline Biologicals S.A. Carrier molecule for antigens
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
PT3506935T (pt) * 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3577130A2 (en) * 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis compositions and methods thereof
MX2020000441A (es) * 2017-07-18 2020-08-17 Serum Inst Of India Pvt Ltd Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma.

Also Published As

Publication number Publication date
SI3009146T1 (sl) 2022-02-28
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
BRPI0612654B1 (pt) 2021-05-04
EP2878307B1 (en) 2019-07-24
JP5718960B2 (ja) 2015-05-13
BRPI0612669A2 (pt) 2010-11-30
JP2008543905A (ja) 2008-12-04
US20130171188A1 (en) 2013-07-04
HUS1200023I1 (hu) 2021-03-29
WO2007000341A2 (en) 2007-01-04
HRP20110567T1 (en) 2011-09-30
NO345422B1 (no) 2021-01-25
CN102526723A (zh) 2012-07-04
SI1896065T2 (sl) 2014-12-31
US8846049B2 (en) 2014-09-30
AP2436A (en) 2012-08-31
MY148110A (en) 2013-02-28
EP3009146A1 (en) 2016-04-20
HK1206587A1 (en) 2016-01-15
ES2621780T3 (es) 2017-07-05
BRPI0612655A8 (pt) 2018-01-30
PE20070123A1 (es) 2007-02-08
EP1896064A2 (en) 2008-03-12
HK1116413A1 (en) 2008-12-24
ES2750243T3 (es) 2020-03-25
NO20076343L (no) 2008-03-25
JP5769688B2 (ja) 2015-08-26
CN103083657A (zh) 2013-05-08
TWI477283B (zh) 2015-03-21
CA2612957C (en) 2016-07-19
HUE046905T2 (hu) 2020-03-30
EA012506B1 (ru) 2009-10-30
MX2007016402A (es) 2008-03-07
AU2006263936A1 (en) 2007-01-04
IL188046A0 (en) 2008-03-20
SI1896061T1 (sl) 2019-10-30
US20190298822A1 (en) 2019-10-03
JP5731737B2 (ja) 2015-06-10
CA2612963A1 (en) 2007-01-04
EP2351578B1 (en) 2017-01-18
BRPI0612670A2 (pt) 2010-11-30
US8883163B2 (en) 2014-11-11
EP1896066B8 (en) 2022-01-19
IL222346A (en) 2015-07-30
PL2351578T3 (pl) 2017-07-31
CN102526723B (zh) 2017-07-07
EP1896061B1 (en) 2019-06-12
ES2377075T3 (es) 2012-03-22
AU2006263963B2 (en) 2010-05-13
BRPI0612669B8 (pt) 2021-05-25
CA2612963C (en) 2016-10-18
AU2010212417A1 (en) 2010-09-09
ES2377075T5 (es) 2016-04-29
AR053935A1 (es) 2007-05-23
KR101321056B1 (ko) 2013-10-30
US20090041802A1 (en) 2009-02-12
CY1112698T1 (el) 2016-02-10
CA2611964A1 (en) 2007-01-04
AU2006263936B2 (en) 2010-05-20
PT2283857T (pt) 2019-10-24
NZ564607A (en) 2011-06-30
AP2007004274A0 (en) 2007-12-31
PT3009146T (pt) 2021-11-30
BRPI0612656A2 (pt) 2010-11-30
BRPI0612654A2 (pt) 2012-10-02
TW200730187A (en) 2007-08-16
US20080193476A1 (en) 2008-08-14
EP2201961B1 (en) 2018-01-24
PL1896061T3 (pl) 2020-02-28
IL188046A (en) 2012-03-29
AR056397A1 (es) 2007-10-10
US9789179B2 (en) 2017-10-17
AU2010203115C1 (en) 2013-05-02
CN103083657B (zh) 2016-06-08
PT1896062E (pt) 2010-05-17
HUE031380T2 (en) 2017-07-28
MA29602B1 (fr) 2008-07-01
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
IL213718A0 (en) 2011-07-31
SI1896062T1 (sl) 2010-07-30
CA2612980C (en) 2019-01-15
NL300549I2 (es) 2017-01-03
BRPI0612655A2 (pt) 2010-11-30
US9931397B2 (en) 2018-04-03
EA200702577A1 (ru) 2008-06-30
CA2611960A1 (en) 2007-01-04
DK2878307T3 (da) 2019-10-07
CA2611964C (en) 2016-11-08
JP2008543904A (ja) 2008-12-04
US8398983B2 (en) 2013-03-19
TW200738259A (en) 2007-10-16
HRP20170457T1 (hr) 2017-05-19
KR20080030577A (ko) 2008-04-04
KR101351870B1 (ko) 2014-02-17
FR22C1008I2 (fr) 2024-01-19
IL214657A0 (en) 2011-09-27
US20130004532A1 (en) 2013-01-03
PE20070499A1 (es) 2007-05-21
DE602006013313D1 (de) 2010-05-12
JP5297800B2 (ja) 2013-09-25
AR056396A1 (es) 2007-10-10
EA012528B1 (ru) 2009-10-30
NZ564605A (en) 2011-01-28
BRPI0612656B1 (pt) 2021-09-08
MX2007016405A (es) 2008-03-07
MY147783A (en) 2013-01-31
MA29603B1 (fr) 2008-07-01
US11241495B2 (en) 2022-02-08
ES2340711T3 (es) 2010-06-08
PL1896062T3 (pl) 2010-08-31
CY1111827T1 (el) 2015-10-07
US20100215686A1 (en) 2010-08-26
SI1896065T1 (sl) 2011-10-28
WO2007000322A1 (en) 2007-01-04
WO2007000341A3 (en) 2007-05-31
NZ564371A (en) 2010-05-28
KR20130086087A (ko) 2013-07-30
LUC00247I2 (es) 2024-10-04
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
AU2006263944B2 (en) 2012-03-01
EP1896063A1 (en) 2008-03-12
KR20080025184A (ko) 2008-03-19
NO342815B1 (no) 2018-08-13
EP1896065B2 (en) 2014-09-03
HRP20100211T1 (hr) 2010-05-31
US20200000911A1 (en) 2020-01-02
EP2283857A1 (en) 2011-02-16
HK1116414A1 (en) 2008-12-24
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
WO2007000343A3 (en) 2007-05-31
CY2012027I2 (el) 2015-10-07
ES2898451T3 (es) 2022-03-07
MA29569B1 (fr) 2008-06-02
PE20110096A1 (es) 2011-03-07
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
ES2901378T3 (es) 2022-03-22
KR101359953B1 (ko) 2014-02-21
UA95238C2 (uk) 2011-07-25
NO20076350L (no) 2008-03-26
CA2612980A1 (en) 2007-01-04
AU2006263965A1 (en) 2007-01-04
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
CA2611960C (en) 2015-05-05
AU2006263963A1 (en) 2007-01-04
PE20110072A1 (es) 2011-02-04
BRPI0612654B8 (pt) 2021-05-25
DK1896065T4 (da) 2014-10-20
LTC1896065I2 (lt) 2025-06-10
PT1896061T (pt) 2019-08-01
KR20080024222A (ko) 2008-03-17
AU2010203115B2 (en) 2012-03-15
ATE536884T1 (de) 2011-12-15
KR20130122810A (ko) 2013-11-08
EP2351578A1 (en) 2011-08-03
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
ES2747025T3 (es) 2020-03-09
JP2015134829A (ja) 2015-07-27
TWI407970B (zh) 2013-09-11
KR20080018226A (ko) 2008-02-27
AU2006263964B2 (en) 2010-05-20
JP2008543907A (ja) 2008-12-04
EA013374B1 (ru) 2010-04-30
CY1109996T1 (el) 2014-09-10
IL188072A (en) 2017-07-31
CA2612957A1 (en) 2007-01-04
PL1896065T5 (pl) 2014-12-31
LU92085I9 (es) 2019-01-04
MX2007016237A (es) 2008-03-07
PL1896063T3 (pl) 2012-04-30
DK1896065T3 (da) 2011-08-29
TWI537001B (zh) 2016-06-11
JP2013018798A (ja) 2013-01-31
SI1896063T1 (sl) 2012-03-30
BRPI0612656A8 (pt) 2018-01-23
WO2007000314A3 (en) 2007-05-31
EP1896062B1 (en) 2010-03-31
EP1896063B2 (en) 2016-03-02
DK2351578T3 (en) 2017-04-24
PT2878307T (pt) 2019-10-24
JP2013209395A (ja) 2013-10-10
JP2008543909A (ja) 2008-12-04
HRP20120102T1 (hr) 2012-02-29
EP1896066B1 (en) 2021-10-27
NO344452B1 (no) 2019-12-09
CY2012027I1 (el) 2015-10-07
JP5037503B2 (ja) 2012-09-26
DK1896062T3 (da) 2010-06-28
IL213795A (en) 2013-05-30
MY147490A (en) 2012-12-14
BRPI0612669B1 (pt) 2019-08-13
EP2878307A1 (en) 2015-06-03
AU2006263964A1 (en) 2007-01-04
WO2007000342A3 (en) 2007-05-31
ATE516816T1 (de) 2011-08-15
SI2283857T1 (sl) 2019-11-29
SI2351578T1 (sl) 2017-05-31
DK2283857T3 (da) 2019-10-28
EP2283857B1 (en) 2019-07-24
US10245317B2 (en) 2019-04-02
US8431136B2 (en) 2013-04-30
DK1896063T3 (da) 2012-03-19
EP1896062A1 (en) 2008-03-12
JP5280199B2 (ja) 2013-09-04
NZ564606A (en) 2010-10-29
US8329184B2 (en) 2012-12-11
PT1896063E (pt) 2012-02-13
EP3009146B1 (en) 2021-10-20
IL188072A0 (en) 2008-03-20
TW201336507A (zh) 2013-09-16
US20090252759A1 (en) 2009-10-08
CY1118646T1 (el) 2017-07-12
EP1896065B1 (en) 2011-07-20
US10166287B2 (en) 2019-01-01
EP1896065A2 (en) 2008-03-12
US9358279B2 (en) 2016-06-07
IL188045A0 (en) 2008-03-20
EA200702576A1 (ru) 2008-06-30
JP5965512B2 (ja) 2016-08-03
BRPI0612670B1 (pt) 2020-04-28
HUS2200002I1 (hu) 2022-12-28
WO2007000342A8 (en) 2008-07-10
HUE047211T2 (hu) 2020-04-28
ES2741529T3 (es) 2020-02-11
EP1896063B1 (en) 2011-12-14
HRP20110567T4 (xx) 2015-01-16
PT1896065E (pt) 2011-08-31
MX2007016403A (es) 2008-03-07
JP2013107913A (ja) 2013-06-06
LT2351578T (lt) 2017-04-10
TWI422386B (zh) 2014-01-11
US20080199490A1 (en) 2008-08-21
JP2008543908A (ja) 2008-12-04
DK1896061T3 (da) 2019-08-26
IL187924A0 (en) 2008-03-20
US20090136541A1 (en) 2009-05-28
NZ564370A (en) 2011-10-28
US20180064806A1 (en) 2018-03-08
US20170065714A1 (en) 2017-03-09
WO2007000327A1 (en) 2007-01-04
AU2006263944A1 (en) 2007-01-04
US9486515B2 (en) 2016-11-08
HUE045482T2 (hu) 2019-12-30
IL213718A (en) 2013-07-31
TW201414490A (zh) 2014-04-16
US20150044253A1 (en) 2015-02-12
MX2007016236A (es) 2008-03-07
BE2012C042I2 (es) 2021-07-19
PL2283857T3 (pl) 2020-02-28
NO345305B1 (no) 2020-12-07
KR101351873B1 (ko) 2014-02-17
KR101532068B1 (ko) 2015-06-29
ATE462444T1 (de) 2010-04-15
EP1896066A2 (en) 2008-03-12
EA012214B1 (ru) 2009-08-28
EP1896061A2 (en) 2008-03-12
EA200702575A1 (ru) 2008-06-30
NO20076363L (no) 2008-03-26
HK1114011A1 (en) 2008-10-24
WO2007000343A2 (en) 2007-01-04
PE20142165A1 (es) 2015-01-09
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
KR101408113B1 (ko) 2014-06-16
BRPI0612670B8 (pt) 2021-05-25
HUE056842T2 (hu) 2022-03-28
AU2010203115A1 (en) 2010-08-12
WO2007000342A2 (en) 2007-01-04
MA29993B1 (fr) 2008-12-01
CN102218138A (zh) 2011-10-19
PL1896065T3 (pl) 2011-12-30
FR22C1008I1 (fr) 2022-04-29
EA200702574A1 (ru) 2008-06-30
PL3009146T3 (pl) 2022-02-07
EP2201961A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
PE20070163A1 (es) Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
MX2022014850A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
UA92579C2 (ru) Поливалентная менингококовая полисахаридно-белковая конъюгированная вакцина
CY1118584T1 (el) Τροποποιημενα σακχαριδια με βελτιωμενη σταθεροτητα σε υδωρ
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
MX337528B (es) Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
CY1112589T1 (el) Ανοσογονος συνθεση που περιεχει ανοσοενισχυτικο
PT1284998E (pt) Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
FI3678654T3 (fi) Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa
CR10123A (es) Vacuna.
MX2019014829A (es) Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
WO2022249106A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
AR082952A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
BR112012019757B8 (pt) Composição imunogênica, e, uso de uma mistura de conjugado de polissacarídeo-proteína multivalente
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
EA200901578A1 (ru) Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
MX365726B (es) Vacuna bacteriana y metodos para la fabricacion de la misma.
MA45283B1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente

Legal Events

Date Code Title Description
FG Grant, registration